Drug-induced pemphigoid: a review of the literature
P.G. Stavropoulos
1st Department of Dermatology/University Clinic, “Andreas Sygros” Hospital, Athens, Greece
Search for more papers by this authorCorresponding Author
E. Soura
1st Department of Dermatology/University Clinic, “Andreas Sygros” Hospital, Athens, Greece
Correspondence: E. Soura. E-mail: [email protected]Search for more papers by this authorC. Antoniou
1st Department of Dermatology/University Clinic, “Andreas Sygros” Hospital, Athens, Greece
Search for more papers by this authorP.G. Stavropoulos
1st Department of Dermatology/University Clinic, “Andreas Sygros” Hospital, Athens, Greece
Search for more papers by this authorCorresponding Author
E. Soura
1st Department of Dermatology/University Clinic, “Andreas Sygros” Hospital, Athens, Greece
Correspondence: E. Soura. E-mail: [email protected]Search for more papers by this authorC. Antoniou
1st Department of Dermatology/University Clinic, “Andreas Sygros” Hospital, Athens, Greece
Search for more papers by this authorConflicts of interest
None declared.Funding sources
None declared.Abstract
Bullous pemphigoid is an acquired autoimmune disease that is characterized by subepidermal blistering and affects mainly the elderly. The pathogenesis of the condition has not yet been fully elucidated, but it is widely accepted that a strong correlation with various medications may exist. In reality, more than 50 different drugs have been associated with the appearance of bullous pemphigoid and as new therapies emerge, this number is very likely to increase. A number of pathogenetic mechanisms have been proposed in the past. It is true that a delicate immunological balance is disturbed in all patients with the disease. The variable effects that may be exhibited by the use of biological drugs could shed some light in this complex immunological behaviour. At the same time, drug-induced bullous pemphigoid is difficult to differentially diagnose from its idiopathic counterpart, as the clinical picture and histopathological findings in both conditions may only have subtle differences. Patients who present with bullous pemphigoid and receive multiple regimens should always be suspected of suffering from the drug-induced variant of the condition. This possibility must be considered, as after the withdrawal of the suspect medication most patients respond rapidly to treatment and do not experience relapses.
References
- 1Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007; 33: 67–77.
- 2Kalaaji NE, Nicolas MEO. Linear basement membrane zone staining pattern. In NE Kalaaji, MEO Nicolas eds. Mayo Clinic Atlas of Immunofluorescence in Dermatology. Mayo Clinic Scientific Press, Taylor & Francis Group, Boca Raton, FL, 2006: 1–3.
10.1201/b14278-2 Google Scholar
- 3Smith EP, Taylor TB, Meyer LJ, Zone JJ. Antigen identification in drug-induced bullous pemphigoid. J Am Acad Dermatol 1993; 29(5 Pt 2): 879–882.
- 4Kashihara M, Danno K, Miyachi Y, Horiguchi Y, Imamura S. Bullous pemphigoid-like lesions induced by phenacetin. Report of a case and an immunopathologic study. Arch Dermatol 1984; 120: 1196–1199.
- 5Alcalay J, David M, Ingber A, Hazaz B, Sandbank M. Bullous pemphigoid mimicking bullous erythema multiforme: an untoward side effect of penicillins. J Am Acad Dermatol 1988; 18(2 Pt 1): 345–349.
- 6Hofmann M, Audring H, Sterry W, Trefzer U. Interleukin-2-associated bullous drug dermatosis. Dermatology 2005; 210: 74–75.
- 7Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991; 30: 307–312.
- 8Lee JJ, Downham T. Furosemide induced bullous pemphigoid: case report and review of literature. J Drugs Dermatol 2006; 5: 562–564.
- 9Bowman C, Delrieu O. Immunogenetics of drug-induced skin blistering disorders. Part I: perspective. Pharmacogenomics 2009; 10: 601–621.
- 10Ahmed AR, Mohimen A, Yunis EJ et al. Linkage of pemphigus vulgaris antibody to the major histocompatibility complex in healthy relatives of patients. J Exp Med 1993; 177: 419–424.
- 11Park B, Sanderson J, Naisbitt D. Drugs as haptens, antigens, and immunogens. In WJ Pichler, ed. Drug Hypersensitivity. Karger, Basel, 2007: 55–65.
10.1159/000104189 Google Scholar
- 12Patsatsi A, Vyzantiadis TA, Chrysomallis F, Devliotou-Panagiotidou D, Sotiriadis D. Medication history of a series of patients with bullous pemphigoid from northern Greece – observations and discussion. Int J Dermatol 2009; 48: 132–135.
- 13Newport MJ, Goetghebuer T, Marchant A. Hunting for immune response regulatory genes: vaccination studies in infant twins. Expert Rev Vaccines 2005; 4: 739–746.
- 14Baum H, Butler P, Davies H, Sternberg MJ, Burroughs AK. Autoimmune disease and molecular mimicry: a hypothesis. Trends Biochem Sci 1993; 18: 140–144.
- 15Ruocco V, de Luca M, Pisani M, de Angelis E, Vitale O, Astarita C. Pemphigus provoked by D(-)penicillamine. An experimental approach using in vitro tissue cultures. Dermatologica 1982; 164: 236–248.
- 16Bean SF, Good RA, Windhorst DB. Bullous pemphigoid in an 11-year-old boy. Arch Dermatol 1970; 102: 205–208.
- 17Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998; 16: 379–387.
- 18Bastuji-Garin S, Joly P, Picard-Dahan C et al. Drugs associated with bullous pemphigoid. A case–control study. Arch Dermatol 1996; 132: 272–276.
- 19Lloyd-Lavery A, Chi Chi C, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use. A UK case–control study. JAMA Dermatol 2013; 149: 58–62.
- 20Ameglio F, D'Auria L, Cordiali-Fei P et al. Bullous pemphigoid and pemphigus vulgaris: correlated behaviour of serum VEGF, sE-selectin and TNF-alpha levels. J Biol Regul Homeost Agents 1997; 11: 148–153.
- 21Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 1999; 79: 288–290.
- 22Kennedy JS, Devillez RL, Henning JS. Recalcitrant cicatricial pemphigoid treated with the anti-TNF-alpha agent etanercept. J Drugs Dermatol 2010; 9: 68–70.
- 23Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 2006; 142: 1457–1461.
- 24Heffernan MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol 2006; 142: 1268–1270.
- 25Nin M, Tokunaga D, Ishii N, Komai A, Hashimoto T, Katoh N. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept. J Dermatol 2013; 40: 55–56.
- 26Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006; 54(3 Suppl. 2): S121–S122.
- 27Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol 2008; 33: 154–155.
- 28Cusano F, Iannazzone SS, Riccio G, Piccirillo F. Coexisting bullous pemphigoid and psoriasis successfully treated with etanercept. Eur J Dermatol 2010; 20: 520.
- 29Bordignon M, Belloni-Fortina A, Pigozzi B, Tarantello M, Alaibac M. Bullous pemphigoid during long-term TNF-alpha blocker therapy. Dermatology 2009; 219: 357–358.
- 30Boussemart L, Jacobelli S, Batteux F et al. Autoimmune bullous skin diseases occurring under anti-tumor necrosis factor therapy: two case reports. Dermatology 2010; 221: 201–205.
- 31Stausbøl-Grøn B, Deleuran M, Sommer Hansen E, Kragballe K. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol 2009; 34: 285–286.
- 32Duong TA, Buffard V, André C et al. Efalizumab-induced bullous pemphigoid. J Am Acad Dermatol 2010; 62: 161–162.
- 33Monnier-Murina K, Du Thanh A, Merlet-Albran S, Guillot B, Dereure O. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto-immune reaction? Dermatology 2009; 219: 89–90.
- 34Liu LY, Bates ME, Jarjour NN, Busse WW, Bertics PJ, Kelly EA. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. J Immunol 2007; 179: 4840–4848.
- 35García-Doval I, Mayo E, Nogueira Fariña J, Cruces MJ. Bullous pemphigoid triggered by influenza vaccination? Ecological study in Galicia, Spain. Br J Dermatol 2006; 155: 820–823.
- 36Lear JT, Tan BB, English JS. Bullous pemphigoid following influenza vaccination. Clin Exp Dermatol 1996; 21: 392.
- 37Fournier B, Descamps V, Bouscarat F, Crickx B, Belaich S. Bullous pemphigoid induced by vaccination. Br J Dermatol 1996; 135: 153–154.
- 38García-Doval I, Rosón E, Feal C, De la Torre C, Rodríguez T, Cruces MJ. Generalized bullous fixed drug eruption after influenza vaccination, simulating bullous pemphigoid. Acta Derm Venereol 2001; 81: 450–451.
- 39Downs AM, Lear JT, Bower CP, Kennedy CT. Does influenza vaccination induce bullous pemphigoid? A report of four cases. Br J Dermatol 1998; 138: 363.
- 40Chacón GR, Sinha AA. Bullous pemphigoid after herpes zoster vaccine administration: association or coincidence? J Drugs Dermatol 2011; 10: 1328–1330.
- 41Lohrisch I, Haustein UF, Baumert A, Szeskus H. Immune response to tetanus toxoid in bullous pemphigoid. Dermatol Monatsschr 1985; 171: 153–157.
- 42Hafiji J, Bhogal B, Rytina E, Burrows NP. Bullous pemphigoid in infancy developing after the first vaccination. Clin Exp Dermatol 2010; 35: 940–941.
- 43Baykal C, Okan G, Sarica R. Childhood bullous pemphigoid developed after the first vaccination. J Am Acad Dermatol 2001; 44(2 Suppl.): 348–350.
- 44Mérida C, Martínez-Escribano JA, Frías JF, Sánchez-Pedreño P, Corbalán R. Bullous pemphigoid in an infant after vaccination. Actas Dermosifiliogr 2005; 96: 255–257.
- 45Valdivielso-Ramos M, Velázquez D, Tortoledo A, Hernanz JM. Infantile bullous pemphigoid developing after hexavalent, meningococcal and pneumococcal vaccinations. An Pediatr (Barc) 2011; 75: 199–202.
- 46Jedlickova H, Racovska J, Niedermeier A, Feit J, Hertl M. Anti-basement membrane zone antibodies in elderly patients with pruritic disorders and diabetes mellitus. Eur J Dermatol 2008; 18: 534–538.
- 47Hirose M, Recke A, Beckmann T et al. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J Immunol 2011; 187: 1176–1183.
- 48Walmsley N, Hampton P. Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid. J Dermatol Case Rep 2011; 5: 74–76.
- 49Chiavérini C, Hamel-Teillac D, Gilbert D, De Prost Y. Absence of anti-BP180 antibodies in mothers of infants with bullous pemphigoid. Br J Dermatol 2006; 54: 839–843.
- 50Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care 2011; 34: 133.
- 51Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26: 249–253.
- 52Aouidad I, Fite C, Marinho E, Deschamps L, Crickx B, Descamps V. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol 2013; 149: 243–245.
- 53Stricklin SM, Stoecker WV, Rader RK, Hood AF, Litt JZ, Schuman TP. Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate. Dermatol Online J 2012; 18: 9.
- 54Nakatani K, Kurose T, Hyo T et al. Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin. Diabetes Ther 2012; 3: 14.
- 55Andukuri R, Drincic A, Rendell M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes 2009; 2: 117–126.
- 56Schmiedl A, Pabst R, Wagner L et al. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol 2008; 181: 1120–1127.
- 57Kruschinski C, Skripuletz T, Bedoui S et al. CD26 (dipeptidyl-peptidase IV)-dependent recruitment of T cells in a rat asthma model. Clin Exp Immunol 2005; 139: 17–24.
- 58Thielitz A, Vetter RW, Schultze B et al. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. J Invest Dermatol 2008; 128: 855–866.
- 59Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case–control study. J Invest Dermatol 2011; 131: 631–636.
- 60Jedlickova H, Hlubinka M, Pavlik T, Semradova V, Budinska E, Vlasin Z. Bullous pemphigoid and internal diseases – a case–control study. Eur J Acad Dermatol Venereol 2010; 20: 96–101.
- 61Li L, Chen J, Wang B, Yao Y, Zuo Y. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160: 1343–1345.
- 62Chorzelski T, Jablonska S, Beutner EH. Bullous pemphigoid: relationship of immunopathology to clinical findings. In EH Beutner, T Chorzelski, SF Bean, eds. Immunopathology of the Skin, 3rd edn. John Willey, New York, 1987: 337–352.
- 63Soni BP, McAlvany JP, Fleischer AB, Sherertz EF. Bullous pemphigoid mimicking contact dermatitis. Contact Dermatitis 1996; 35: 314.
- 64Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br J Dermatol 2012; 167: 1200–1214.
- 65Diab M, Coloe J, Bechtel MA. Bullous pemphigoid precipitated by galantamine hydrobromide. Cutis 2009; 83: 139–140.
- 66Aksakal BA, Ozsoy E, Arnavut O, Ali Gürer M. Oral terbinafine-induced bullous pemphigoid. Ann Pharmacother 2003; 37: 1625–1627.
- 67Kalińska-Bienias A, Rogoziński TT, Woźniak K, Kowalewski C. Can pemphigoid be provoked by lisinopril? Br J Dermatol 2006; 155: 854–855.